- Home
- CTNM vs EDIT Comparison
CTNM vs EDIT Comparison
Compare CTNM & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- EDIT
- Stock Information
- Founded
- CTNM 2009
- EDIT 2013
- Country
- CTNM United States
- EDIT United States
- Employees
- CTNM N/A
- EDIT N/A
- Industry
- CTNM
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTNM
- EDIT Health Care
- Exchange
- CTNM Nasdaq
- EDIT Nasdaq
- Market Cap
- CTNM 328.1M
- EDIT 269.8M
- IPO Year
- CTNM 2024
- EDIT 2016
- Fundamental
- Price
- CTNM $10.93
- EDIT $2.45
- Analyst Decision
- CTNM Strong Buy
- EDIT Buy
- Analyst Count
- CTNM 5
- EDIT 10
- Target Price
- CTNM $20.40
- EDIT $4.13
- AVG Volume (30 Days)
- CTNM 166.5K
- EDIT 2.3M
- Earning Date
- CTNM 10-30-2025
- EDIT 11-10-2025
- Dividend Yield
- CTNM N/A
- EDIT N/A
- EPS Growth
- CTNM N/A
- EDIT N/A
- EPS
- CTNM N/A
- EDIT N/A
- Revenue
- CTNM N/A
- EDIT $46,383,000.00
- Revenue This Year
- CTNM N/A
- EDIT N/A
- Revenue Next Year
- CTNM N/A
- EDIT N/A
- P/E Ratio
- CTNM N/A
- EDIT N/A
- Revenue Growth
- CTNM N/A
- EDIT N/A
- 52 Week Low
- CTNM $3.35
- EDIT $0.91
- 52 Week High
- CTNM $16.25
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- CTNM 47.95
- EDIT 34.53
- Support Level
- CTNM $10.46
- EDIT $2.45
- Resistance Level
- CTNM $13.09
- EDIT $2.73
- Average True Range (ATR)
- CTNM 0.98
- EDIT 0.20
- MACD
- CTNM 0.08
- EDIT -0.01
- Stochastic Oscillator
- CTNM 29.68
- EDIT 21.32
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.